Company / Free Cash Flow
Zenas BioPharma, Inc. Free Cash Flow History
FY2023-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Free Cash Flow
-$172.4M
FY2025
5-year range
-$172.4M / -$30.5M
FY2023-FY2025
Trend
-464.2%
vs FY2024
Sector context
#141 of 194
Health Care
What the data says
Free Cash Flow changed -464% YoY in FY2025, a notable deviation from the 2-year average annual change of -232%.
Based on SEC 10-K filings.
-$172M in FY2025.
Declined from -$31M to -$172M over the past 2 years.
Health Care sector context is included.
Free Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#141 of 194 in Health CareTop 73% of 194This company -$172.4M Sector average $470.6M
▼
-136.6% below sector average
Key checks
Key Insights
- In FY2025, free cash flow decreased 464.2% year-over-year.
- Ranks #141 out of 194 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -3.51 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Free Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$172.4M | -464.2% |
| FY2024 | -$30.5M | +0.0% |
| FY2023 | -$30.5M | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026